[Ip-health] "IP as a power tool for development" is back for a Nov. 2013 conference organized by South Africa's Companies and IP Commission

Thiru Balasubramaniam thiru at keionline.org
Fri Aug 2 08:35:07 PDT 2013


During Kamil Idris's tenure at the helm of the World Intellectual Property
Organization, a hackneyed mantra of the organization was "Intellectual
property: a power tool for economic growth". It would appear that South
Africa's Companies and IP Commission (CIPC) along with the National IP
Management Office (NIPMO) of South Africa seek to resurrect this concept at
the conference entitled, “Creating and Leveraging Intellectual Property in
Developing Countries: A Power Tool for Social and Economic Growth” to be
held in Durban from 17-20 November 2013.

According to the organizers, "this conference follows on from the
successful meeting of the BRICS Heads of Patent Offices in Durban in May
2013, and comes at an important time—not just in the progress of South
Africa, but throughout all of Africa, as well as the BRICS nations, as the
countries work to shape the future of IP."

Speakers include:

"McLean Sibanda (CEO, Innovation Hub of Guateng Provence and President of
the African Division of the International Association of Science Parks);
Justice Joel Ngugi (High Court of Kenya); Morne Barradas (Lead IP Legal
Advisor: Risk and Compliance, Sasol Group Services (Sasolburg, South
Africa)); Chief Judge James Smith (U.S. Patent and Trademark Office, Patent
Trial and Appeal Board (inv)); Roy Waldron (Chief IP Counsel, Pfizer); Phil
Johnson (Chief IP Counsel, Johnson & Johnson); James Pooley (Deputy
Director, WIPO); Maaike va Velzen (IP & Standards, General Manager, Philips
Group Innovation); Todd Dickinson (Executive Director, AIPLA); Steve Sammut
(Professor, Wharton School of Business and Burrill Venture Partner); Gordon
Myers (Chief Counsel, Technology and Private Equity, IFC Legal Department
of the World Bank); Yonah Seleti (Acting Deputy Director General, Human
Capital and Knowledge Systems, Department of Science and Technology of
South Africa); Michal Preminger, PhD, MBA (Executive Director of the Office
of Technology Development, Harvard Medical School); Konji Sebati (Director
of Department of Traditional Knowledge and Global Challenges, WIPO); Ellis
Owusu-Dabo (Scientific Director of the Kumasi Centre for Collaborative
Research in Tropical Medicines at Kwame Nkrumah University of Science and
Technology (Ghana)); Professor Dennis C. Liotta (Samuel Chandler Dobbs
Professor of Chemistry at Emory University and Founder of Emory Institute
for Drug Discovery and DRIVE (Drug Innovation Ventures at Emory)); Jennifer
Dent (President, BIO Ventures for Global Health); and Professor Joseph
Strauss (Professor of Law at Universities of Munich and Ljubljana; Chair,
IP and Innovation Management, University of South Africa and Professor of
George Washington Law School)."

One of the speakers for this November conference is Phil Johnson (Chief IP
Counsel, Johnson & Johnson). Another invited speaker is Roy Waldron (Chief
IP Counsel, Pfizer <http://keionline.org/node/1689>) who provided testimony
on 13 March 2013 to the Trade Subcommittee of the House Ways and Means
Committee at a hearing on U.S.-India Trade Relations: Opportunities and
Challenges. As noted in our previous blog,

"Waldron's written testimony included a variety of complaints about the
India patent law, focusing on the failures to obtain patents for some
products, including those denied under Section 3(d) of the India patent
law, the India system of pre-grant opposition to patents under Section
25(1) of the India patent act, the Nexavar compulsory licensing case under
Section 84 of the India patent act, the requirements for local
manufacturing, and the new proposals to grant compulsory licenses under
Section 92 of the India patent act. Waldron also asserted that India had
not complied with TRIPS requirements for the protection of test data, and
complained that drug regulatory authorities did not block drug approval
where there are assertions of patent protection."

Given that this international conference intends to create synergies
between senior officials in the South African government and "international
key government, organization, industrial and academic leaders from Africa
and other BRICS countries, as well as the U.S. and Europe, to form a
fertile environment for discussion, networking and relationships", J&J's
and Pfizer's comments will be under close scrutiny.

More details on the conference can be found

More information about the Ip-health mailing list